Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2026 / Articles / March / Building Quality into Advanced Therapies from Day One
Development & Clinical Regulation & Standards Outsourcing Sponsored

Building Quality into Advanced Therapies from Day One

Why early, risk-based thinking is critical in cell and gene therapy development

03/13/2026 5 min read Interview

Sponsored By

ProBio US

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Top Institutions

Share

Top Institutions in Advanced Therapies Quality Assurance and Regulatory Science

Institutions are ranked based on their leadership in advanced therapy manufacturing, regulatory science, and quality assurance research, as well as their pioneering work in cell and gene therapy development and collaboration with regulatory agencies like the FDA to establish GMP frameworks for emerging modalities.

  • #1

    National Institutes of Health (NIH) - Center for Cellular Engineering

    Bethesda, MD

    NIH leads in translational research and regulatory science for advanced therapies, with extensive programs in cell and gene therapy development and a strong focus on GMP-compliant manufacturing processes for rare diseases.

    Key Differentiators

    • Cell and Gene Therapy
    • Regulatory Science
    • Quality Assurance
  • #2

    Stanford University School of Medicine - Institute for Stem Cell Biology and Regenerative Medicine

    Stanford, CA

    Stanford is a pioneer in regenerative medicine and advanced therapy development, with strong expertise in establishing quality systems and GMP standards for novel therapeutic modalities.

    Key Differentiators

    • Stem Cell Therapy
    • Gene Therapy
    • Quality Systems
  • #3

    University of Pennsylvania - Center for Advanced Cellular Therapeutics

    Philadelphia, PA

    UPenn is a leader in CAR-T and gene therapy clinical development with integrated GMP manufacturing and quality assurance programs ensuring regulatory compliance and patient safety.

    Key Differentiators

    • CAR-T Therapy
    • Gene Therapy
    • Regulatory Compliance
  • #4

    Mayo Clinic - Center for Regenerative Medicine

    Rochester, MN

    Mayo Clinic integrates clinical research with GMP manufacturing expertise, focusing on quality assurance in advanced therapies for rare and ultra-rare diseases.

    Key Differentiators

    • Regenerative Medicine
    • Quality Assurance
    • Rare Disease Therapies
  • #5

    Fred Hutchinson Cancer Center

    Seattle, WA

    Fred Hutch is recognized for its pioneering work in cell and gene therapies, with strong emphasis on manufacturing quality and regulatory compliance in clinical translation.

    Key Differentiators

    • Cell Therapy
    • Gene Therapy
    • Manufacturing Quality

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Recommended

Related Content

The (Un)fairer Sex?
Development & Clinical
The (Un)fairer Sex?

November 6, 2014

0 min read

Our understanding of the differences in male and female biology is constantly growing – but can we translate that knowledge into better healthcare for all?

Sex Matters
Development & Clinical
Sex Matters

November 6, 2014

0 min read

New NIH policies aim to correct the sex bias in preclinical research

The Shingles Vaccine and Dementia
Drug Discovery Research News Development & Clinical
The Shingles Vaccine and Dementia

April 10, 2025

2 min read

Studies have suggested that the RZV shingles vaccine can lower the risk of dementia; GSK is now investigating further

FDA to Phase Out Animal Testing
Regulation & Standards Business & Trends Development & Clinical
FDA to Phase Out Animal Testing

April 11, 2025

2 min read

FDA to phase out mandatory animal testing with human-relevant methods for drug development

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: